Advertisement

Pharmaceutical Research

, 35:165 | Cite as

Preclinical Development of Cell-Based Products: a European Regulatory Science Perspective

  • James W. McBlane
  • Parvinder Phul
  • Michaela Sharpe
Research Paper
  • 58 Downloads
Part of the following topical collections:
  1. Living Cell Medicines: Perspectives and Challenges

Abstract

Purpose

This article describes preclinical development of cell-based medicinal products for European markets and discusses European regulatory mechanisms open to developers to aid successful product development. Cell-based medicinal products are diverse, including cells that are autologous or allogeneic, have been genetically modified, or not, or expanded ex vivo, and applied systemically or to an anatomical site different to that of their origin; comments applicable to one product may not be applicable to others, so bespoke development is needed, for all elements - quality, preclinical and clinical.

Methods

After establishing how the product is produced, proof of potential for therapeutic efficacy, and then safety, of the product need to be determined. This includes understanding biodistribution, persistence and toxicity, including potential for malignant transformation. These elements need to be considered in the context of the intended clinical development.

Results

This article describes regulatory mechanisms available to developers to support product development that aim to resolve scientific issues prior to marketing authorization application, to enable patients to have faster access to the product than would otherwise be the case.

Conclusions

Developers are encouraged to be aware of both the scientific issues and regulatory mechanisms to ensure patients can be supplied with these products.

Keywords

biodistribution cell therapy regulatory science toxicity tumorigenicity 

Abbreviations

CAT

Committee for Advanced Therapies

CBMP

cell based medicinal product

CHMP

Committee for Human Medicinal Products

CPWP

Cell Products Working Party

DNA

deoxyribonucleic acid

EC

European Commission

EMA

European Medicines Agency

FDA

Food and Drug Administration

GLP

Good Laboratory Practice

hPSC

human pluripotent stem cells

HSC

hematopoietic stem cells

ICH

International Conference on Harmonisation

MSC

mesenchymal stromal cells

SAWP

Scientific Advice Working Party

SWP

Safety Working Party

Notes

Acknowledgments and Disclosures

The authors did not receive any funding from any agency in the public, commercial or not-for-profit sectors to write this article. JW McBlane is an alternate member of the Committee for Advanced Therapies (CAT) and of the Scientific Advice Working Party (SAWP) of the Committee for Human Medicinal products (CHMP), both operated by the European Medicines Agency. However, views expressed in this article represent only those of the authors and not those of these committees and working party.

References

  1. 1.
    McBlane JW. Preclinical safety testing for cell-based products using animals. Biologicals. 2015a;43(5):425–8.CrossRefPubMedGoogle Scholar
  2. 2.
    Aiuti A, Roncarolo MG, Naldini L. Gene therapy for ADA-SCID, the first marketing approval of an ex vivo gene therapy in Europe: paving the road for the next generation of advanced therapy medicinal products. EMBO Mol Med. 2017;9:737–40.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    McBlane JW. Regulatory landscape for cell therapy – EU view. Biologicals. 2015b;43(5):433–6.CrossRefPubMedGoogle Scholar
  4. 4.
    Yano K, Watanabe N, Tsuyuki K, Ikawa T, Kasanuki H, Yamato M. Regulatory approval for autologous human cells and tissue products in the United States, the European Union, and Japan. Regen Ther. 2015;1:45–56.CrossRefGoogle Scholar
  5. 5.
    Vestergaard HT, D'Apote L, Schneider CK, Herberts C. The evolution of nonclinical regulatory science: advanced therapy medicinal products as a paradigm. Mol Ther. 2013 Sep;21(9):1644–8.CrossRefPubMedGoogle Scholar
  6. 6.
    Dorotka R, Bindreiter U, Macfelda K, Windberger U, Nehrer S. Marrow stimulation and chondrocyte transplantation using a collagen matrix for cartilage repair. Osteoarthr Cartil. 2005;13:655–64.CrossRefPubMedGoogle Scholar
  7. 7.
    Schüssler-Lenz M, Beneu C, Menezes-Ferreira M, Jekerle V, Bartunek J, Chamuleau S, et al. Cell-based therapies for cardiac repair: a meeting report on scientific observations and European regulatory viewpoints. Eur Heart J. 2016;18:133–41.CrossRefGoogle Scholar
  8. 8.
    CHMP/410869/2006 Guideline on Human Cell-Based Medicinal Products.Google Scholar
  9. 9.
    ICHS6(R1) Preclinical safety evaluation of biotechnology-derived pharmaceuticals.Google Scholar
  10. 10.
    ICHM3(R2) Non-clinical safety studies for the conduct of human clinical trials and marketing authorisation for pharmaceuticals.Google Scholar
  11. 11.
    CHMP/SWP/1042/99 (R1) Guideline on repeated dose toxicity.Google Scholar
  12. 12.
    Blaich G, Baumann A, Kronenberg S, de haan L, Ulrich P, Richter WF, et al. Non-clinical safety evaluation of biotherapeutics – challenges, opportunities and new insights. Regul Toxicol Pharmacol. 2016;80:S1–S14.CrossRefGoogle Scholar
  13. 13.
    Goldring CE, Duffy PA, Benvenisty N, Andrews PW, Ben-David U, Eakins R, et al. Assessing the safety of stem cells. Cell Stem Cell. 2011;8:618–28.CrossRefPubMedGoogle Scholar
  14. 14.
    Hayakawa T, Aoi T, Bravery C, Hoogendoorn K, Knezevic I, Koga J, et al. Report of the international conference on regulatory endeavors towards the sound development of human cell therapy products. Biologicals. 2015;43(5):283–97.CrossRefPubMedGoogle Scholar
  15. 15.
    Bailey AM. Balancing tissue and tumor formation in regenerative medicine. Sci Transl Med. 2013;4(147):147fs128.Google Scholar
  16. 16.
    Sharpe M, Leoni G, Barry J, Schutte R, Mount N. Non-clinical studies for cell-based medicines. In: Vives J, Carmona G, editors. Guide to cell therapy GxP: quality standards in the development of cell-based medicines in non-pharmaceutical environments. Cambridge: Academic Press; 2015. p. 49–106.Google Scholar
  17. 17.
    Kooijman M, van Meer PJ, Gispen-de Wied CC, Moors EH, Hekkert MP, Schellekens H. The risk-based approach to ATMP development - generally accepted by regulators but infrequently used by companies. Regul Toxicol Pharmacol. 2013;67(2):221–5.CrossRefPubMedGoogle Scholar
  18. 18.
    Thomson JA. Embryonic stem cell lines derived from human blastocysts. Science 1999. 1998;282(5391):1145–7.Google Scholar
  19. 19.
    Blum B, Benvenisty N. The tumorigenicity of diploid and aneuploid human pluripotent stem cells. Cell Cycle. 2009;8(23):3822–30.CrossRefPubMedGoogle Scholar
  20. 20.
    Dhodapkar MV. Antigen-bearing immature dendritic cells induce peptide-specific CD8+ regulatory T cells in vivo in humans. Blood. 2002;100(1): 174–7.CrossRefPubMedGoogle Scholar
  21. 21.
    Sharpe ME, Morton D, Rossi A. Nonclinical safety strategies for stem cell therapies. Toxicol Appl Pharmacol. 2012;262:223–31.CrossRefPubMedGoogle Scholar
  22. 22.
    Conesa, C, Doss MX, Antzelevitch C, Sachinidis A, Sancho J, Carrodeguas JA. Identification of specific pluripotent stem cell death-inducing small molecules by chemical screening. Stem Cell Rev. 2012;8(1):116–27.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Lee MO, Moon SH, Jeong HC, Yi JY, Lee TH, Shim SH, et al. Inhibition of pluripotent stem cell-derived teratoma formation by small molecules. Proc Natl Acad Sci U S A. 2013;110(35):E3281–90.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Amps K, Andrews PW, Anyfantis G, Armstrong L, Avery S, Baharvand H, et al. Screening ethnically diverse human embryonic stem cells identifies a chromosome 20 minimal amplicon conferring growth advantage. Nat Biotechnol. 2011;29(12):1132–44.CrossRefPubMedGoogle Scholar
  25. 25.
    Baker D, Hirst AJ, Gokhale PJ, Juarez MA, Williams S, Wheeler M, et al. Detecting genetic mosaicism in cultures of human pluripotent stem cells. Stem Cell Reports. 2016;7(5):998–1012.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Jacobs K, Zambelli F, Mertzanidou A, Smolders I, Geens M, Nguyen HT, et al. Higher-density culture in human embryonic stem cells results in DNA damage and genome instability. Stem Cell Reports. 2016;6(3):330–41.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Yoshihara M, Hayashizaki Y, Murakawa Y. Genomic instability of iPSCs: challenges towards their clinical applications. Stem Cell Rev. 2017;13(1):7–16.CrossRefPubMedGoogle Scholar
  28. 28.
    Avery S, Hirst AJ, Baker D, Lim CY, Alagaratnam S, Skotheim RI, et al. BCL-XL mediates the strong selective advantage of a 20q11.21 amplification commonly found in human embryonic stem cell cultures. Stem Cell Reports. 2013;1(5):379–86.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Nguyen HT, Geens M, Mertzanidou A, Jacobs K, Heirman C, Breckpot K, et al. Gain of 20q11.21 in human embryonic stem cells improves cell survival by increased expression of Bcl-xL. Mol Hum Reprod. 2014;20(2):168–77.CrossRefPubMedGoogle Scholar
  30. 30.
    Adjiri A. DNA mutations may not be the cause of cancer. Oncol Ther. 2017;5(1):85–101.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Barkholt L, Flory E, Jekerle V, Lucas-Samuel S, Ahnert P, Bisset L, et al. Risk of tumorigenicity in mesenchymal stromal cell-based therapies - bridging scientific observations and regulatory viewpoints. Cytotherapy. 2013;15(7):753–9.CrossRefPubMedGoogle Scholar
  32. 32.
    Phillips MI, Tang YL. Genetic modification of stem cells for transplantation. Adv Drug Deliv Rev. 2008;60(2):160–72.CrossRefPubMedGoogle Scholar
  33. 33.
    Ferrua F, Aiuti A. Twenty-five years of gene therapy for ADA-SCID: from bubble babies to an approved Drug. Hum Gene Ther. 2017;28(11):972–81.Google Scholar
  34. 34.
    Hacein-Bey-Abina S, Garrigue A, Wang GP, Soulier J, Lim A, Morillon E, et al. Insertional oncogenesis in 4 patiens after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest. 2008;118(9):3132–42.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Braun CJ, Boztug K, Paruzynski A, Witzel M, Schwarzer A, Rothe M, et al. Gene therapy for Wiskott-Aldrich syndrome - long-term efficacy and genotoxicity. Sci Transl Med. 2014;6(227):227ra233.CrossRefGoogle Scholar
  36. 36.
    Ott MG, Schmidt M, Schwarzwaelder K, Stein S, Siler U, Koehl U, et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med. 2006;12(4):401–9.CrossRefPubMedGoogle Scholar
  37. 37.
    Persons DA, Baum C. Solving the problem of gamma-retroviral vectors containing long terminal repeats. Mol Ther. 2011;19(2):229–31.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Cavazzana-Calvo M, Payen E, Negre O, Wang G, Hehir K, Fusil F, Down J, Denaro M, Brady T, Westerman K, Cavallesco R, Gillet-Legrand B, Caccavelli L, Sgarra R, Maouche-Chretien L, Bernaudin F, Girot R, Dorazio R, Mulder GJ, Polack A, Bank A, Soulier J, Larghero J, Kabbara N, Dalle B, Gourmel B, Socie G, Chretien S, Cartier N, Aubourg P, Fischer A, Cornetta K, Galacteros F, Beuzard Y, Gluckman E, Bushman F, Hacein-Bey-Abina S, Leboulch P. Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia. Nature 2010 467;(7313):318–322.Google Scholar
  39. 39.
    Bailey AM, Mendicino M, Au P. An FDA perspective on preclinical development of cell-based regenerative medicine products. Nat Biotechnol. 2014;32(8):721–3.CrossRefPubMedGoogle Scholar
  40. 40.
    Flory E, Reinhardt J. European regulatory tools for advanced therapy medicinal products. Transfus Med Hemother. 2013;40(6):409–12.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Directive 2004/10/EC of the European Parliament and of the Council of 11 February 2004 on the harmonisation of laws, regulations and administrative provisions relating to the application of the principles of good laboratory practice and the verification of their application for tests on chemical substances.Google Scholar
  42. 42.
    Regulation (EC) 1272/2008 of the European Parliament and of the Council of 16 December 2008 on classification, labelling and packaging of substances and mixtures, amending and repealing Directives 67/548/EEC and 1999/45/EC, and amending Regulation (EC) No 1907/2006.Google Scholar
  43. 43.
    Volk SW, Theoret C. Translating stem cell therapies: the role of companion animals in regenerative medicine. Wound Repair Regen. 2013;21(3):382–92.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Cavagnaro J, Silva Lima B. Regulatory acceptance of animal models of disease to support clinical trials of medicines and advanced therapy medicinal products. Eur J Pharmacol. 2015;759:51–62.CrossRefPubMedGoogle Scholar
  45. 45.
    Regulation (EC) 1394/2007 of the European Parliament and of the Council of 13 November 2007 on Advanced Therapy Medicinal Products and Amending Directive 2001/83/EC and Regulation (EC) No 726/2004.Google Scholar
  46. 46.
    EMA/CAT/486831/2008/corr Guideline on the Minimum Quality and Non-Clinical Data for Certification of Advanced Therapy Medicinal Products.Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • James W. McBlane
    • 1
  • Parvinder Phul
    • 1
  • Michaela Sharpe
    • 2
  1. 1.Licensing DivisionMedicines & Healthcare Products Regulatory AgencyLondonUK
  2. 2.Nonclinical Safety, Cell and Gene Therapy CatapultGuy’s HospitalLondonUK

Personalised recommendations